Copyright: ©Author(s) 2026.
World J Transplant. Jun 18, 2026; 16(2): 118012
Published online Jun 18, 2026. doi: 10.5500/wjt.v16.i2.118012
Published online Jun 18, 2026. doi: 10.5500/wjt.v16.i2.118012
Table 6 Currently approved respiratory syncytial virus vaccines in chronic liver disease patients/Liver transplantation recipients
| Vaccine (brand) | Recommended adult use | Clinical notes in CLD /LT |
| RSVpreF (Abrysvo®, Pfizer), RSVpreF3 OA (Arexvy®, GSK), mRNA-1345 (mRESVIA®, Moderna) | A single i.m. dose in adults with CLD aged 60-74 years prior to RSV season; a single intramuscular dose to adults undergoing LT at least 2 weeks prior to LT, or at least 6 months afterwards | No recommendations on booster dosing are yet available |
- Citation: Papic N, Kosuta I, Ljubas D, Vrsaljko N, Sesa V, Domislovic V, Ahsan S, Mrzljak A. Not just another shot: Tailoring vaccination in the era of modern liver transplantation. World J Transplant 2026; 16(2): 118012
- URL: https://www.wjgnet.com/2220-3230/full/v16/i2/118012.htm
- DOI: https://dx.doi.org/10.5500/wjt.v16.i2.118012